Relevant bibliographies by topics / Hematopoietic Stem Cell Transplants

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Hematopoietic Stem Cell Transplants'

Author: Grafiati
Published: 4 June 2021
Last updated: 2 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Hematopoietic Stem Cell Transplants.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Hematopoietic Stem Cell Transplants"

1

Mahmoud, Hossam Kamel, Gamaleldin Mohamed Fathy, Alaa Elhaddad, Omar Abdelrahman Fahmy, Mohamed Abdelmooti, Raafat Abdelfattah, and Mahmoud Tarek Sayed Ahmed Bokhary. "HEMATOPOIETIC STEM CELL TRANSPLANTATION IN EGYPT CHALLENGES AND SOLUTIONS." Mediterranean Journal of Hematology and Infectious Diseases 12, no. 1 (April 27, 2020): e2020023. http://dx.doi.org/10.4084/mjhid.2020.023.

Full text
Abstract:
Hematopoietic stem cell transplantation (HSCT) is now an established treatment modality with definitive indications for many hematological disorders. However, this line of treatment requires tremendous resources, and it becomes increasingly difficult for transplanters practicing in the developing world to reconcile the difference between what is possible and what is available. On the basis of 30 years of experience and more than 4250 transplants , this article will focus on the challenges faced our HSCT program and how they were solved. The HSCT program in Egypt started in 1989 on a narrow scale and since that time we faced many challenges.In 1997, the transplant rate increased dramatically with the opening of many HSCT units distributed allover Egypt. Our team is registered in the Center for International Blood and Marrow Transplant Research ,and the number of transplants performed till December 2019 exceeded 4000 cases (60% allogeneic and 40% autologous).
APA, Harvard, Vancouver, ISO, and other styles
2

Alshemmari, Salem, Reem Ameen, and Javid Gaziev. "Haploidentical Hematopoietic Stem-Cell Transplantation in Adults." Bone Marrow Research 2011 (July 13, 2011): 1–10. http://dx.doi.org/10.1155/2011/303487.

Full text
Abstract:
Haploidentical hematopoietic stem-cell transplantation is an alternative transplant strategy for patients without an HLA-matched donor. Still, only half of patients who might benefit from transplantation are able to find an HLA-matched related or unrelated donor. Haploidentical donor is readily available for many patients in need of immediate stem-cell transplantation. Historical experience with haploidentical stem-cell transplantation has been characterised by a high rejection rate, graft-versus-host disease, and transplant-related mortality. Important advances have been made in this field during the last 20 years. Many drawbacks of haploidentical transplants such as graft failure and significant GVHD have been overcome due to the development of new extensive T cell depletion methods with mega dose stem-cell administration. However, prolonged immune deficiency and an increased relapse rate remain unresolved problems of T cell depletion. New approaches such as partial ex vivo or in vivo alloreactive T cell depletion and posttransplant cell therapy will allow to improve immune reconstitution in haploidentical transplants. Results of unmanipulated stem-cell transplantation with using ATG and combined immunosuppression in mismatched/haploidentical transplant setting are promising. This paper focuses on recent advances in haploidentical hematopoietic stem-cell transplantation for hematologic malignancies.
APA, Harvard, Vancouver, ISO, and other styles
3

Angelucci, Emanuele. "Hematopoietic Stem Cell Transplantation in Thalassemia." Hematology 2010, no. 1 (December 4, 2010): 456–62. http://dx.doi.org/10.1182/asheducation-2010.1.456.

Full text
Abstract:
Abstract Almost 30 years have passed since the first successful hematopoietic stem cell transplantation in thalassemia and that first patient is now a healthy young adult with a completely normal life. Since that time, more than 3000 such transplants have been performed worldwide. This review provides a brief history of hematopoietic stem cell transplantation in thalassemia and reassesses current clinical results with the objective to provide outcome predictions based on modern transplant technologies. The role of hematopoietic stem cell transplantation in the oral chelation era and implications for possible closure in the approach to future gene therapy will also be discussed.
APA, Harvard, Vancouver, ISO, and other styles
4

Fernandes, Juliana Folloni, Fabio Rodrigues Kerbauy, Andreza Alice Feitosa Ribeiro, Jose Mauro Kutner, Luis Fernando Aranha Camargo, Adalberto Stape, Eduardo Juan Troster, et al. "Allogeneic hematopoietic stem cell transplantation in children with primary immunodeficiencies: Hospital Israelita Albert Einstein experience." Einstein (São Paulo) 9, no. 2 (June 2011): 140–44. http://dx.doi.org/10.1590/s1679-45082011ao2007.

Full text
Abstract:
Objective: To report the experience of a tertiary care hospital with allogeneic hematopoietic stem cell transplantation in children with primary immunodeficiencies. Methods: Seven pediatric patients with primary immunodeficiencies (severe combined immunodeficiency: n = 2; combined immunodeficiency: n = 1; chronic granulomatous disease: n = 1; hyper-IgM syndrome: n = 2; and IPEX syndrome: n = 1) who underwent eight hematopoietic stem cell transplants in a single center, from 2007 to 2010, were studied. Results: Two patients received transplants from HLA-identical siblings; the other six transplants were done with unrelated donors (bone marrow: n = 1; cord blood: n = 5). All patients had pre-existing infections before hematopoietic stem cell transplants. One patient received only anti-thymocyte globulin prior to transplant, three transplants were done with reduced intensity conditioning regimens and four transplants were done after myeloablative therapy. Two patients were not evaluated for engraftment due to early death. Three patients engrafted, two had primary graft failure and one received a second transplant with posterior engraftment. Two patients died of regimen related toxicity (hepatic sinusoidal obstruction syndrome); one patient died of progressive respiratory failure due to Parainfluenza infection present prior to transplant. Four patients are alive and well from 60 days to 14 months after transplant. Conclusion: Patients’ status prior to transplant is the most important risk factor on the outcome of hematopoietic stem cell transplants in the treatment of these diseases. Early diagnosis and the possibility of a faster referral of these patients for treatment in reference centers may substantially improve their survival and quality of life.
APA, Harvard, Vancouver, ISO, and other styles
5

Smith, Clayton. "Hematopoietic Stem Cells and Hematopoiesis." Cancer Control 10, no. 1 (January 2003): 9–16. http://dx.doi.org/10.1177/107327480301000103.

Full text
Abstract:
Background The highly orchestrated process of blood cell development and homeostasis is termed “hematopoiesis.” Understanding the biology of hematopoietic stem cells as well as hematopoiesis is important to developing improved treatments for hematologic malignancies, congenital disorders, chemotherapy-related cytopenias, and blood and marrow transplants. Methods The author reviews the current state of the art regarding hematopoietic stem cells and hematopoiesis. Results Several new concepts, including stem cell plasticity, suggest the possibility that stem cells may have the ability to differentiate into other tissues in addition to blood cells. Conclusions While much is known about hematopoietic stem cells and hematopoiesis, much remains to be clarified about the environmental and genetic processes that govern the growth and development of the blood system. In addition, careful studies remain to be conducted to determine whether hematopoietic stem cells can differentiate into extra-hematopoietic tissues.
APA, Harvard, Vancouver, ISO, and other styles
6

Hamerschlak, Nelson. "Haploidentical transplantation of hematopoietic stem cells." Revista da Associação Médica Brasileira 62, suppl 1 (October 2016): 29–33. http://dx.doi.org/10.1590/1806-9282.62.suppl1.29.

Full text
Abstract:
SUMMARY Objective: To review and discuss the literature on hematopoietic stem cell transplantation (HSCT) with haploidentical donors in Brazil. Method: Literature review. Results: The haploidentical hematopoietic stem cell transplantations have become a safe option in hematology since the 80s, with the possibility of ex-vivo T-cell depletion. However, its broad use worldwide occurred with the advent of haploidentical nonmyeloablative transplants using in vivo T-cell depletion with the administration of post-transplant cyclophosphamide. The results were encouraging, despite the increased risk of infection and post-transplantation recurrence. Recent publications on acute myeloid leukemia, myelodysplastic syndrome and Hodgkin’s lymphoma have shown similar results among haploidentical, unrelated and related full-match transplants. Obviously, these findings of retrospective studies should be confirmed by clinical trials. Conclusions: Transplantation with haploidentical donor has shown to be feasible in Brazil and the first publications and results are showing encouraging results.
APA, Harvard, Vancouver, ISO, and other styles
7

Nilsson, Susan K., Mark S. Dooner, Candi Y. Tiarks, Heinz-Ulrich Weier, and Peter J. Quesenberry. "Potential and Distribution of Transplanted Hematopoietic Stem Cells in a Nonablated Mouse Model." Blood 89, no. 11 (June 1, 1997): 4013–20. http://dx.doi.org/10.1182/blood.v89.11.4013.

Full text
Abstract:
Abstract Increasingly, allogeneic and even more often autologous bone marrow transplants are being done to correct a wide variety of diseases. In addition, autologous marrow transplants potentially provide an opportune means of delivering genes in transfected, engrafting stem cells. However, despite its widespread clinical use and promising gene therapy applications, relatively little is known about the mechanisms of engraftment in marrow transplant recipients. This is especially so in the nonablated recipient setting. Our data show that purified lineage negative rhodamine 123/Hoechst 33342 dull transplanted hematopoietic stem cells engraft into the marrow of nonablated syngeneic recipients. These cells have multilineage potential, and maintain a distinct subpopulation with “stem cell” characteristics. The data also suggests a spatial localization of stem cell “niches” to the endosteal surface, with all donor cells having a high spatial affinity to this area. However, the level of stem cell engraftment observed following a transplant of “stem cells” was significantly lower than that expected following a transplant of the same number of unseparated marrow cells from which the purified cells were derived, suggesting the existence of a “nonstem cell facilitator population,” which is required in a nonablated syngeneic transplant setting.
APA, Harvard, Vancouver, ISO, and other styles
8

Fernandez-Viña, Marcelo A., Tao Wang, Stephanie J. Lee, Michael Haagenson, Mahmoud Aljurf, Medhat Askar, Minoo Battiwalla, et al. "Identification of a permissible HLA mismatch in hematopoietic stem cell transplantation." Blood 123, no. 8 (February 20, 2014): 1270–78. http://dx.doi.org/10.1182/blood-2013-10-532671.

Full text
Abstract:
Key Points Mismatches in alleles C*03:03/C*03:04 were most frequent (68.7%) among the transplants with a single allele level mismatch in HLA-C. The 7/8 C*03:03/C*03:04 mismatch group was not significantly different from the 8/8 HLA matched transplants in any transplant outcome.
APA, Harvard, Vancouver, ISO, and other styles
9

Collin, Matthew P., Derek N. J. Hart, Graham H. Jackson, Gordon Cook, James Cavet, Stephen Mackinnon, Peter G. Middleton, and Anne M. Dickinson. "The fate of human Langerhans cells in hematopoietic stem cell transplantation." Journal of Experimental Medicine 203, no. 1 (January 3, 2006): 27–33. http://dx.doi.org/10.1084/jem.20051787.

Full text
Abstract:
Langerhans cells (LC) and other antigen-presenting cells are believed to be critical in initiating graft versus host responses that influence the outcome of allogeneic hematopoietic stem cell transplantation. However, their fate in humans is poorly understood. We have sought to define the effect of conditioning regimes and graft versus host disease (GVHD) on the survival of recipient LC and reconstitution of donor cells after transplant. Confocal microscopy of epidermal sheets shows that full intensity transplant (FIT) depletes LC more rapidly than reduced intensity transplant (RIT) at day 0, although the nadir is similar in both at 14–21 d. Recovery occurs rapidly within 40 d in the absence of acute GVHD, but is delayed beyond 100 d when GVHD is active. LC chimerism was determined in sex-mismatched transplants using a two-step Giemsa/fluorescence in situ hybridization assay on isolated cells. Acquisition of donor chimerism at 40 d is more rapid after FIT (97%) than RIT (36.5%), irrespective of blood myeloid engraftment. At 100 d, all transplants achieve at least 90% LC donor chimerism and over half achieve 100%. Complete donor chimerism is associated with prior acute cutaneous GVHD, suggesting a role for allogeneic T cells in promoting LC engraftment.
APA, Harvard, Vancouver, ISO, and other styles
10

Tricot, Guido, Sundar Jagannath, David H. Vesole, Dwayne Bracy, K. R. Desikan, David Siegel, and Bart Barlogie. "Hematopoietic Stem Cell Transplants for Multiple Myeloma." Leukemia & Lymphoma 22, no. 1-2 (January 1996): 25–36. http://dx.doi.org/10.3109/10428199609051725.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Hematopoietic Stem Cell Transplants"

1

Tay, Jason. "Donor selection for patients undergoing allogeneic hematopoietic stem cell transplantation: Assessment of the priorities of Canadian hematopoietic stem cell transplant physicians." Thesis, University of Ottawa (Canada), 2009. http://hdl.handle.net/10393/28202.

Full text
Abstract:
Allogeneic Hematopoietic Stem Cell Transplantation is applied in the management of cancer. It involves myeloablative chemoradiotherapy followed by infusion of donor stem cells. The characteristics of the donor stern cells influences transplant outcomes which itself, is dependent on the donor characteristics. The purpose of this thesis was to explore preferences over donor characteristics. A systematic review was performed to identify all donor characteristics associated with outcome. Eight traditional and 5 non-traditional characteristics were identified. The results of the review were used to inform a survey of the Canadian Bone Marrow Transplant Group which primarily includes transplant physicians. An online survey and conjoint analysis of Canadian Bone Marrow Transplant Group members was performed to define relative importance of donor characteristics. Canadian Bone Marrow Transplant Group members, including transplant physicians caring for adults strongly indicate preference for donors related to recipients (HR 2.97) over the donor's age, gender and cytomegalovirus compatibility.
APA, Harvard, Vancouver, ISO, and other styles
2

Nikolich‐Zugich, Tijana. "Effects of High Vs. Reduced‐Dose Melphalan For Autologous Bone Marrow Transplantation in Multiple Myeloma On Pulmonary Function: A Longitudinal Study." Thesis, The University of Arizona, 2017. http://hdl.handle.net/10150/623514.

Full text
Abstract:
A Thesis submitted to The University of Arizona College of Medicine - Phoenix in partial fulfillment of the requirements for the Degree of Doctor of Medicine.
Bone marrow transplants (BMT, also hematopoietic stem cell transplants or HSCT/SCT) are one of the greatest medical achievements of the 20th century. They offer a treatment for a host of malignant and nonmalignant hematopoietic disorders, genetic diseases and solid tumors that could otherwise be fatal. Studies have found that 60% of patients undergoing BMT develop pulmonary complications (PC), and 1/3 of those require intensive care after transplantation. Despite the potential pneumotoxicity of induction agents, to date there have been no longitudinal studies following pulmonary function in this high‐risk patient population. This study reviewed patient who underwent autogeneic bone marrow transplant for multiple myeloma at Banner University Medical Center – Tucson (formerly University of Arizona Health Network) from January 1, 2003 through December 31, 2013. Pretransplant evaluatin and pulmonary function testing data were obtained and stratified between high dose (standard) Melphalan (200 mg/ms2) and reduced dose (140 mg/ms2). Statistically significant differences were present between the 2 groups at baseline for DLCO but disappeared at 6 and 12‐month followup, while a statistically significant difference for FEV1/FVC ratio was seen at baseline and 6 months but disappeared at 12‐month follow‐up. There were no statistically significant differences seen with FEV1 between the two groups. Given there is no difference in mortality and relapse outcomes between the groups, the standard of care dosing for Melphalan is not associated with an increase in pulmonary morbidity.
APA, Harvard, Vancouver, ISO, and other styles
3

Olcina, Elias, and Larsson Arvid. "The Use of Opioid Substances after undergoing Hematopoietic Stem Cell Transplant." Thesis, Uppsala universitet, Statistiska institutionen, 2020. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-413717.

Full text
Abstract:
In this paper, we are going to study the use of opioid substances after undergoing a Hematopoietic Stem Cell transplant in Sweden. The purpose of the study is divided into two parts, where the first objective is to display the use of opioids within the population using descriptive statistics. The second objective is to model the effect of opioid substances on survival using Cox Proportional Hazard regression. From the descriptive part, we can see that women tend to take opioids to a slightly greater extent than men, and that there are great differences among age groups were younger patients tend to withdraw more opioids. We create three different models measuring the effect of opioid use within the 43 first days after transplant on survival, correcting for four potential confounders: sex, age at transplant, source of transplant and relationship to the donor. The first two models are fitted with different measurements of survival time, and the third model is a stratified Cox regression based on model 2. The three models somewhat differ from each other in terms of estimated hazard ratios, however, we cannot show a statistically significant effect of opioid use within the first 43 days on survival in any of the models.
APA, Harvard, Vancouver, ISO, and other styles
4

Nelson, Ashley M. "Sleep Disruption Among Cancer Patients Following Autologous Hematopoietic Stem Cell Transplantation." Scholar Commons, 2016. http://scholarcommons.usf.edu/etd/6547.

Full text
Abstract:
Background: Sleep disruption is one of the most commonly reported quality of life concerns among cancer patients who have undergone hematopoietic stem cell transplantation (HSCT). Despite the high percentage of patients reporting sleep concerns, relatively little research has characterized sleep problems or explored relationships with psychological factors. In addition, no studies have used actigraph technology to characterize sleep issues among transplant recipients. Method: Autologous HSCT recipients who were 6 to 18 months post-transplant were invited to participate. Patients completed self-report measures of cancer-related distress, fear of cancer recurrence, dysfunctional cognitions about sleep, and maladaptive sleep behaviors upon enrollment, wore an actigraph and completed a sleep log at home for 7 days, and completed a self-report measure of sleep disruption on day 7 of the study. Results: 84 autologous HSCT recipients (age M = 60, 45% female) were enrolled and provided complete data. Forty-one percent of patients met criteria for sub-clinical or clinical insomnia based on patient self-report. Examination of actigraph data indicated that certain aspects of sleep were poorer than others (wake after sleep onset M = 66 minutes; total sleep time M = 6.5 hours; sleep efficiency M = 78%; sleep onset latency M = 21 minutes). Measures of cancer-related distress, fear of cancer recurrence, cognitive distortions, and maladaptive behavioral patterns were related to subjectively reported sleep disruption, p’s < .05, but were not related to objectively measured sleep disruption. Further examination revealed that the cognitive and behavioral factors accounted for the largest unique variance in subjectively reported sleep disruption. Conclusion: Results from the present study suggest that many HSCT recipients continue to experience sleep disruption during the survivorship period following transplant. Cancer-specific factors, dysfunctional cognitions about sleep, and maladaptive sleep behaviors were related to self-reported sleep disruption and are ripe targets for a cognitive behavioral intervention.
APA, Harvard, Vancouver, ISO, and other styles
5

Hackenmueller, Stacy Sharon. "A Retrospective Chart Review: Caloric Adequacy within Adult Hematopoietic Stem Cell Transplantation." The Ohio State University, 2012. http://rave.ohiolink.edu/etdc/view?acc_num=osu1338314832.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Hunt, Lawrence Taylor, John Zachary Riddle, and Ali McBride. "Effectiveness of Prophylactic Fluconazole at Low Doses for Allogeneic Hematopoietic Stem Cell Transplant Patients." The University of Arizona, 2016. http://hdl.handle.net/10150/613995.

Full text
Abstract:
Class of 2016 Abstract
Objectives: The purpose of this study was to evaluate if fluconazole 200 mg is an acceptable alternative to the fluconazole 400 mg for fungal prophylaxis in allogenic hematopoietic stem cell patients. Lower fluconazole doses will decrease cost of therapy and may reduce adverse events associated with higher doses. Methods: This study was a retrospective chart review conducted at the Arizona Cancer Center. A total of 58 patients qualified for the study. Primary endpoints were number of days on fluconazole 200 mg and type and number of fungal infections that occurred within 1 year post transplant. Results: Out of the fifty-eight patients who qualified for the study, only eight patients had a breakthrough fungal infection while on 200 mg (13.7%) after one year. Three of those eight were identified as having systemic fungal infections (5.2%). Conclusions: Fluconazole 200 mg is a reasonable low-cost and low side effect alternative to fluconazole 400 mg for antifungal prophylaxis in allogenic hematopoietic stem cell patients.
APA, Harvard, Vancouver, ISO, and other styles
7

McBrien, Marie. "The effect of Poly I:C induced inflammation on hematopoietic stem and progenitor cell behaviour in the zebrafish hematopoietic transplant model." Thesis, Imperial College London, 2017. http://hdl.handle.net/10044/1/55871.

Full text
Abstract:
Hematopoietic stem cells are a small but significant population of cells fundamental for generating and maintaining the hematopoietic system. These cells are used in the treatment of cancer and auto-immune patients. Studies in mammals suggest that inflammation and infection can modulate the biology of these cells, affecting their location, self-renewal capacity and directing differentiation. The aim of this work was to study the effect of repeated stimulation on the hematopoietic stem and progenitor (HSPCs) population in zebrafish (Danio rerio) to benefit from the live imaging potential of this model organism. It was hypothesised that early post-transplant HSPC behaviour (e.g. lodgement in the niche, self-renewal, mobilisation and differentiation) could be observed and would be indicative of the success or failure of HCT. Double transgenic Tg (cd41:GFP; lysc:dsRed) donors, in which HSPCs express green fluorescent protein (GFP+) and myeloid cells express red fluorescent protein (dsRed+) were used. HSPCs were sorted from donor whole kidney marrow (WKM) and transplanted into irradiated optically-transparent recipients, which were then imaged using wide-field microscopy, individually tracked for survival and hematopoietic reconstitution was assessed after 28 days by flow cytometry. Indeed, initial experiments showed that early observations of cells in the WKM correlated with hematopoietic recovery and survival of recipients, although the strength of the correlation was not sufficiently powerful for predicting recipient outcome. This refinement of the HCT protocol lead to the potentiality of studying the behaviour of HSPCs in the context of inflammation. Inflammation was initiated with repeated intra-peritoneal injections of the viral mimic Polyinosinic:polycytidylic acid (poly I:C) in either the donor or recipient prior to transplant. Poly I:C injection of donors prior to transplant causes HSPCs to colonise the recipient WKM at a greater rate than HSPCs from sham (PBS-injected) donors. However, this did not appear to affect recipient survival or WKM reconstitution at 28 days. Poly I:C injection of recipients prior to transplant did not affect early post-transplant repopulation of the WKM, myelopoiesis, recipient survival, or WKM reconstitution at 28 days. Future work will use competitive transplants to confirm these findings and will explore alternative inflammation models. Furthermore, the confounding factor of irradiation-caused inflammation will be mitigated by transplanting HSPCs into optically-transparent bloodless recipients. Overall, this thesis has demonstrated that the zebrafish can provide valuable in vivo data for studying HSPC behaviour in the recipient post-transplant.
APA, Harvard, Vancouver, ISO, and other styles
8

Corraliza, Márquez Ana Maria. "Immune mechanisms involved in inducing remission in Crohn’s disease patients undergoing hematopoietic stem cell transplant." Doctoral thesis, Universitat de Barcelona, 2019. http://hdl.handle.net/10803/667770.

Full text
Abstract:
Crohn’s disease [CD] is a chronic inflammatory disease of the intestinal tract with considerable heterogeneity among affected patients in terms of disease phenotype and therapeutic responses. Despite the increase in the number of drugs approved for the management of CD, a significant percentage of patients remain unresponsive or lose response over time to treatments, and eventually require surgery to control disease activity and/or complications. Nonetheless, in a fraction of these refractory patients, intestinal resection may not be possible due to disease location, extension or previous surgeries. For such patients, autologous hematopoietic stem cell transplantation [HSCT] represents a potential salvage therapy despite the risks associated with this procedure. Stem cell transplantation is an accepted therapy for hematological disorders, aplastic anemia and immunodeficiencies. In the context of autoimmune diseases, the serendipitous benefits of transplantation were initially reported in patients suffering from both immune-mediated diseases and hematological disorders. This led to trials that have shown the efficacy of autologous HSCT in treating an array of autoimmune diseases including refractory severe multiple sclerosis, systemic lupus erythematosus, juvenile idiopathic arthritis, rheumatoid arthritis and, more recently, CD. The benefit of HSCT in autoimmunity is thought to originate from the ability of intense immune depletion to eliminate auto-reactive cells regardless of their specificity. This would lead to de novo generation of immune cells that could re-establish tolerance, although no objective evidence of this ‘resetting’ has been reported thus far. To explore this hypothesis, we group of CD patients [n = 18] receiving autologous HSCT, with 50% of them achieving endoscopic drug-free remission. To elucidate the mechanisms driving efficacy, we monitored changes after HSCT in blood and intestine immune-cell composition. CD patients [n = 22] receiving anti-tumor necrosis factor [TNF]-α were included for comparison. Severe immune ablation followed by HSCT induced dramatic changes in both peripheral blood T and B cells in all patients regardless of the efficacy of the treatment. Endoscopic remission at week 52 following HSCT was associated with significant intestinal transcriptional changes. A comparison of the remission signature with that of anti-TNFα identified both common and unique genes in the HSCT-induced response. Based on deconvolution analysis of intestinal biopsy transcriptome data, we show that response to HSCT, but not to anti-TNFα, is associated with an expansion of naïve B-cells, as seen in blood, and a decrease in the memory resting T- cell content. As expected, endoscopic remission, in response to both HSCT and anti-TNFα, led to a significant reduction in intestinal neutrophil and M1 macrophage content. HSCT dramatically renewed the pre-existing T-cell receptor [TCR] repertoire; however, persistent high-frequency TCR clones were detected in all patients in both blood and biopsy throughout the first year of follow-up. The number of persistent resident T cell clonotypes in tissue after treatment decreased in patients that achieve endoscopic remission. Furthermore, we found that low TCR peripheral diversity at baseline, and up to 1 year after HSCT, were associated with a lack of response to the immunoablative protocol. Peripheral blood immune remodeling after HSCT does not predict efficacy. In contrast, a profound intestinal T-cell depletion that is maintained long after transplant is associated with mucosal healing following HSCT, but not anti-TNFα.
Se ha demostrado la eficacia del trasplante hematopoyético de células madre (THCM) en pacientes con enfermedad de Crohn severamente refractaria. La hipótesis aceptada es que el proceso de THCM elimina células auto-reactivas, devolviendo así la tolerancia. No obstante, no existen estudios específicos y exhaustivos sobre la reconstitución inmune en pacientes con enfermedad de Crohn tratados con THCM. En esta tesis, monitorizamos una cohorte de 18 pacientes con enfermedad de Crohn refractaria que recibieron trasplante autólogo de células madre hematopoyéticas, de los cuales el 50% consiguieron la remisión endoscópica sin tratamiento de mantenimiento. Para elucidar los mecanismos que determinan la eficacia, monitorizamos los cambios después de THCM en la composición de células inmunes tanto en sangre como en tejido intestinal. Como resultado, observamos que la ablación inmune producida durante el TCMH induce cambios dramáticos en las células T y B en sangre en todos los pacientes, independientemente de la eficacia del tratamiento. La remisión endoscópica en la semana 52 posterior al TCMH se asoció con cambios transcripcionales intestinales significativos. Una comparación de la transcripción en remisión con la de la remisión inducida por fármaco identificó genes comunes y únicos en la respuesta inducida por el TCMH. A través de un análisis de deconvolución de los datos del transcriptoma de la biopsia intestinal, mostramos que la respuesta al TCMH, pero no a fármaco inmuno- modulador, se asocia con una expansión de las células B naïve y una disminución en el contenido de células T memoria. Como se esperaba, la remisión endoscópica, en respuesta a tanto a TCMH como a fármaco, condujo a una reducción significativa en el contenido de neutrófilos intestinales y macrófagos M1 La remodelación inmune de la sangre periférica después del TCMH no predice la eficacia. No obstante, la depleción de las células T intestinales mantenida un año después del trasplante se asocia con la curación mucosa después del TCMH.
APA, Harvard, Vancouver, ISO, and other styles
9

Morrison, Caroline Frances. "Self-Management by Adolescents and Young Adults Following a Stem Cell Transplant." University of Cincinnati / OhioLINK, 2016. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1472719290.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Giest, S. "Detection, monitoring & clonal characterisation of human cytomegalovirus specific CD8+ T cells in hematopoietic stem cell transplant patients." Thesis, University College London (University of London), 2008. http://discovery.ucl.ac.uk/1444178/.

Full text
Abstract:
The human cytomegalovirus (CMV) can cause significant morbidity and mortality in haematopoietic stem cell transplant (HSCT) patients. The immunosuppressed state of the hosts facilitates dissemination of the virus and disease. In contrast, CD8+ T cells in healthy individuals control viral dissemination and maintain a balance between antiviral host defence and replication of the virus that leads to viral latency with sporadic, harmless reactivations. Current pharmacological intervention in the HSCT setting is associated with significant toxicity and is counteracted by the occurrence of resistant viral strains. Alternative approaches, such as adoptive therapy of CMV specific CD8+ T cells are of great interest in the field. So far, levels of such cells correlating with protection against CMV disease in patients were only shown for cells targeting two different viral epitopes. The project described in this thesis investigates CD8+ T cell responses to several common CMV targets presented by different human leukocyte antigens in the HSCT setting. Results demonstrate significant differences between the numbers of different CMV specific CD8+ T cells that, in the presence of CD4+ T cell help, inversely correlate with the ability to detect CMV reactivation. Findings also demonstrate significant differences in the diversity of T cell receptors (TCRs) used by the different CMV specific CD8+ T cells isolated from HSCT patients. These findings are clinically relevant in that the quantity of cells shown to correlate with protection against CMV could be used as a marker for monitoring patients' immune status towards CMV. This may aid clinical decision making to limit pharmacological intervention to those patients at highest risk for the development of CMV disease. It may also aid the monitoring of the effectiveness of adoptive therapy trials. Therapeutic use of cells with high TCR diversity may be advantageous over other cells in that they may impede the development of CMV immune escape in patients.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Hematopoietic Stem Cell Transplants"

1

Maziarz, Richard T., and Susan Slater. Blood and marrow transplant handbook: Comprehensive guide for patient care. New York: Springer, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Carreras, Enric. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. Cham: Springer Nature, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lazarus, Hillard M., Robert Peter Gale, Armand Keating, Andrea Bacigalupo, Reinhold Munker, Kerry Atkinson, and Syed Ali Abutalib, eds. Hematopoietic Cell Transplants. Cambridge: Cambridge University Press, 2017. http://dx.doi.org/10.1017/9781316335727.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

service), SpringerLink (Online, ed. Hematopoietic Stem Cell Biology. Totowa, NJ: Humana Press, a part of Springer Science+Business Media, LLC, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Bishop, Michael R., ed. Hematopoietic Stem Cell Transplantation. Boston, MA: Springer US, 2009. http://dx.doi.org/10.1007/978-0-387-78580-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Bunting, Kevin D., ed. Hematopoietic Stem Cell Protocols. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-182-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Godin, Isabelle, and Ana Cumano. Hematopoietic Stem Cell Development. Boston, MA: Springer US, 2006. http://dx.doi.org/10.1007/978-0-387-33535-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Bunting, Kevin D., and Cheng-Kui Qu, eds. Hematopoietic Stem Cell Protocols. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-1133-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Kondo, Motonari, ed. Hematopoietic Stem Cell Biology. Totowa, NJ: Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60327-347-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Soiffer, Robert J., ed. Hematopoietic Stem Cell Transplantation. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-438-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Hematopoietic Stem Cell Transplants"

1

Guba, Susan C., and Bart Barlogie. "Stem Cell Transplants for Hematopoietic Malignancies." In Molecular Biology of B-Cell and T-Cell Development, 505–21. Totowa, NJ: Humana Press, 1998. http://dx.doi.org/10.1007/978-1-4757-2778-4_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Gale, R. P., A. Butturini, and P. R. Henon. "Transplants of Blood-Derived Hematopoietic Cells." In Peripheral Blood Stem Cell Autografts, 19–25. Berlin, Heidelberg: Springer Berlin Heidelberg, 1993. http://dx.doi.org/10.1007/978-3-642-75717-4_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Giralt, Sergio, Issa Khouri, and Richard Champlin. "Non Myeloablative “Mini Transplants”." In Advances in Allogeneic Hematopoietic Stem Cell Transplantation, 97–108. Boston, MA: Springer US, 1999. http://dx.doi.org/10.1007/978-1-4615-4987-1_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Nathan, Paul, Adam Gassas, and Jonathan Wasserman. "Hematopoietic Stem Cell Transplant." In Handbook of Long Term Care of The Childhood Cancer Survivor, 179–208. Boston, MA: Springer US, 2015. http://dx.doi.org/10.1007/978-1-4899-7584-3_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Palma, Julia, and Cristián Sotomayor. "Hematopoietic Stem Cell Transplant." In Pediatric Hematology-Oncology in Countries with Limited Resources, 393–403. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-3891-5_27.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Hansen, John A., Jorge Sierra, Effie W. Petersdorf, Paul J. Martin, and Claudio Anasetti. "Hematopoietic Stem Cell Transplants from Unrelated Donors." In Bone Marrow Transplantation, 233–45. Tokyo: Springer Japan, 1996. http://dx.doi.org/10.1007/978-4-431-68320-9_29.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Gratwohl, Alois. "Global Perspectives on Hematopoietic Stem Cell Transplants (HSCTs)." In Establishing a Hematopoietic Stem Cell Transplantation Unit, 1–11. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-59358-6_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Marty, Francisco M., and Lindsey R. Baden. "Infection in the Hematopoietic Stem Cell Transplant Recipient." In Hematopoietic Stem Cell Transplantation, 421–48. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-438-4_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Cordonnier, Catherine. "Pneumonia After Hematopoietic Stem Cell Transplantation." In Transplant Infections, 251–69. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-28797-3_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Martino, Rodrigo. "Toxoplasmosis After Hematopoietic Stem Cell Transplantation." In Transplant Infections, 773–80. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-28797-3_42.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Hematopoietic Stem Cell Transplants"

1

Ohsuga, Mieko, Yuma Tada, and Jun Ishikawa. "Interactive environment for hematopoietic stem-cell transplant patients." In 2017 International Conference on Virtual Rehabilitation (ICVR). IEEE, 2017. http://dx.doi.org/10.1109/icvr.2017.8007469.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

England, Kristen A., Kevin V. Tram, Andrew Price, Steve D. Shapiro, Bruce Blazar, and Angela Panoskaltsis-Mortari. "Beta6 Integrin And Obliterative Bronchiolitispost-hematopoietic Stem Cell Transplant." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a1993.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Farhat, R., A. C. Miller, and D. Picker. "Polymicrobial Lung Abscess Complicating Autologous Hematopoietic Stem Cell Transplant." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a6855.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Abdulai, Raolat M., and Bekele Afessa. "Diffuse Alveolar Hemorrhage In Hematopoietic Stem Cell Transplant Recipients." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a4471.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Tran, Betty T., and Jason W. Chien. "Cigarette Smoking And Allogeneic Hematopoietic Stem Cell Transplant Outcomes." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a5434.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sivasankaran, Adarsh, Vladimir Cherkassky, Mark Albrecht, Eric Williams, and Martin Maiers. "Donor Selection for Hematopoietic Stem Cell Transplant Using Cost-Sensitive SVM." In 2015 IEEE 14th International Conference on Machine Learning and Applications (ICMLA). IEEE, 2015. http://dx.doi.org/10.1109/icmla.2015.166.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Gitman, Melissa R., Shirish Huprikar, and Gopi Patel. "Trichosporon Asahii Pulmonary Infection In A Hematopoietic Stem Cell Transplant Recipient." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a5467.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Mourin, G., L. Couderc, J. Vernant, F. Mellot, F. Suarez, P. Honderlick, E. Catherinot, and E. Rivaud. "Ribavirin for Respiratory Syncytial Virus Bronchiolitis in Hematopoietic Stem Cell Transplant Patients." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a5958.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Mcandrew, N. S., J. L. Guttormson, J. Erickson, and J. J. Patel. "Experiences of Family Caregivers of Critically Ill Hematopoietic Stem Cell Transplant Patients." In American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a3187.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Abdulai, Raolat M., and Bekele Afessa. "Peri-Engraftment Respiratory Distress Syndrome (Perds) In Hematopoietic Stem Cell Transplant (HSCT) Recipients." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a1146.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Hematopoietic Stem Cell Transplants"

1

Dorshkind, Kenneth. Effects of Hematopoietic Stem Cell Age on CML Disease Progression. Fort Belvoir, VA: Defense Technical Information Center, March 2006. http://dx.doi.org/10.21236/ada451341.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Laudenslager, Mark, Teresa Simoneau, Susan Mikulich-Gilbertson, Benjamin Brewer, Kristin Kilbourn, Jon Gutman, and Peter McSweeney. Using a Program to Lower Stress for Caregivers of Patients With Cancer Who Have Received Stem Cell Transplants. Patient-Centered Outcomes Research Institute® (PCORI), January 2020. http://dx.doi.org/10.25302/1.2020.ce.13086208.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Liu, Huan, Hui Huang, Jia Guo, Chengyuan Li, Jiandang Zhou, Qifeng Yi, Wei Hua, and Lihong Zeng. Effects of aerobic exercise on fatigue in patients with hematopoietic stem cell transplantation: a meta analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2021. http://dx.doi.org/10.37766/inplasy2021.5.0110.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ji, Conghua, Rongchen Dai, Hanting Wu, Qiushuang Li, Shan Liu, Peijie He, Juan Liang, and Qing Guo. Efficacy and safety of hematopoietic stem cell transplantation for hematologic malignancies: A protocol for an overview of systematic reviews and meta-analyses. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2021. http://dx.doi.org/10.37766/inplasy2021.5.0064.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Yin, Xuewei, Liming Yu, Lingling Yin, Yan Wang, Wei Zheng, Jie Xu, Yueli Liu, et al. Efficacy and safety of tandem versus single autologous hematopoietic stem cell transplantation for the treatment of multiple myeloma: A protocol for systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2021. http://dx.doi.org/10.37766/inplasy2021.6.0112.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Herpes zoster vaccine reduces chances of shingles after stem cell transplants. National Institute for Health Research, November 2019. http://dx.doi.org/10.3310/signal-000835.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Hematopoietic Stem Cell Transplants' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography